Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis

Gillian L. Currie, Helena N. Angel-Scott, Lesley Colvin, Fala Cramond, Kaitlyn Hair, Laila Khandoker, Jing Liao, Malcolm R. MacLeod, Sarah K. McCann, Rosie Morland, Nicki Sherratt, Robert Stewart, Ezgi Tanriver-Ayde, James Thomas, Qianying Wang, Rachel Wodarski, Ran Xiong, Andrew S. C. Rice, Emily S. Sena (Lead / Corresponding author)

Research output: Contribution to journalArticle

3 Citations (Scopus)
62 Downloads (Pure)

Abstract

We report a systematic review and meta-analysis of research using animal models of chemotherapy-induced peripheral neuropathy (CIPN). We systematically searched 5 online databases in September 2012 and updated the search in November 2015 using machine learning and text mining to reduce the screening for inclusion workload and improve accuracy. For each comparison, we calculated a standardised mean difference (SMD) effect size, and then combined effects in a random-effects meta-analysis. We assessed the impact of study design factors and reporting of measures to reduce risks of bias. We present power analyses for the most frequently reported behavioural tests; 337 publications were included. Most studies (84%) used male animals only. The most frequently reported outcome measure was evoked limb withdrawal in response to mechanical monofilaments. There was modest reporting of measures to reduce risks of bias. The number of animals required to obtain 80% power with a significance level of 0.05 varied substantially across behavioural tests. In this comprehensive summary of the use of animal models of CIPN, we have identified areas in which the value of preclinical CIPN studies might be increased. Using both sexes of animals in the modelling of CIPN, ensuring that outcome measures align with those most relevant in the clinic, and the animal's pain contextualised ethology will likely improve external validity. Measures to reduce risk of bias should be employed to increase the internal validity of studies. Different outcome measures have different statistical power, and this can refine our approaches in the modelling of CIPN.

Original languageEnglish
Article numbere3000243
Pages (from-to)1-34
Number of pages34
JournalPLoS Biology
Volume17
Issue number5
DOIs
Publication statusPublished - 20 May 2019

Fingerprint

Chemotherapy
peripheral nervous system diseases
systematic review
Peripheral Nervous System Diseases
meta-analysis
drug therapy
Meta-Analysis
Animals
Animal Models
animal models
Drug Therapy
Outcome Assessment (Health Care)
Ethology
Pain Clinics
animals
Data Mining
artificial intelligence
Workload
limbs (animal)
animal behavior

Cite this

Currie, G. L., Angel-Scott, H. N., Colvin, L., Cramond, F., Hair, K., Khandoker, L., ... Sena, E. S. (2019). Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis. PLoS Biology, 17(5), 1-34. [e3000243]. https://doi.org/10.1371/journal.pbio.3000243
Currie, Gillian L. ; Angel-Scott, Helena N. ; Colvin, Lesley ; Cramond, Fala ; Hair, Kaitlyn ; Khandoker, Laila ; Liao, Jing ; MacLeod, Malcolm R. ; McCann, Sarah K. ; Morland, Rosie ; Sherratt, Nicki ; Stewart, Robert ; Tanriver-Ayde, Ezgi ; Thomas, James ; Wang, Qianying ; Wodarski, Rachel ; Xiong, Ran ; Rice, Andrew S. C. ; Sena, Emily S. / Animal models of chemotherapy-induced peripheral neuropathy : a machine-assisted systematic review and meta-analysis. In: PLoS Biology. 2019 ; Vol. 17, No. 5. pp. 1-34.
@article{eaeb51aa90004aa288d8abad7e43ac55,
title = "Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis",
abstract = "We report a systematic review and meta-analysis of research using animal models of chemotherapy-induced peripheral neuropathy (CIPN). We systematically searched 5 online databases in September 2012 and updated the search in November 2015 using machine learning and text mining to reduce the screening for inclusion workload and improve accuracy. For each comparison, we calculated a standardised mean difference (SMD) effect size, and then combined effects in a random-effects meta-analysis. We assessed the impact of study design factors and reporting of measures to reduce risks of bias. We present power analyses for the most frequently reported behavioural tests; 337 publications were included. Most studies (84{\%}) used male animals only. The most frequently reported outcome measure was evoked limb withdrawal in response to mechanical monofilaments. There was modest reporting of measures to reduce risks of bias. The number of animals required to obtain 80{\%} power with a significance level of 0.05 varied substantially across behavioural tests. In this comprehensive summary of the use of animal models of CIPN, we have identified areas in which the value of preclinical CIPN studies might be increased. Using both sexes of animals in the modelling of CIPN, ensuring that outcome measures align with those most relevant in the clinic, and the animal's pain contextualised ethology will likely improve external validity. Measures to reduce risk of bias should be employed to increase the internal validity of studies. Different outcome measures have different statistical power, and this can refine our approaches in the modelling of CIPN.",
author = "Currie, {Gillian L.} and Angel-Scott, {Helena N.} and Lesley Colvin and Fala Cramond and Kaitlyn Hair and Laila Khandoker and Jing Liao and MacLeod, {Malcolm R.} and McCann, {Sarah K.} and Rosie Morland and Nicki Sherratt and Robert Stewart and Ezgi Tanriver-Ayde and James Thomas and Qianying Wang and Rachel Wodarski and Ran Xiong and Rice, {Andrew S. C.} and Sena, {Emily S.}",
note = "This work is part of the National centre for Replacement, Refinement and Reduction (NC3Rs, https://www.nc3rs.org.uk/) funded project; Reduction and refinement in animal models of neuropathic pain: using systematic review and meta-analysis (NC/K000659/1)- GLC, ES, MM, ASCR, JL, RS, NS, FC. This work is also part of the Europain Collaboration, which has received support from the Innovative Medicines Initiative Joint Undertaking, under grant agreement no 115007, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and EFPIA companies’ in kind contribution- ASCR. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 702213-SKM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",
year = "2019",
month = "5",
day = "20",
doi = "10.1371/journal.pbio.3000243",
language = "English",
volume = "17",
pages = "1--34",
journal = "PLoS Biology",
issn = "1544-9173",
publisher = "Public Library of Science",
number = "5",

}

Currie, GL, Angel-Scott, HN, Colvin, L, Cramond, F, Hair, K, Khandoker, L, Liao, J, MacLeod, MR, McCann, SK, Morland, R, Sherratt, N, Stewart, R, Tanriver-Ayde, E, Thomas, J, Wang, Q, Wodarski, R, Xiong, R, Rice, ASC & Sena, ES 2019, 'Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis', PLoS Biology, vol. 17, no. 5, e3000243, pp. 1-34. https://doi.org/10.1371/journal.pbio.3000243

Animal models of chemotherapy-induced peripheral neuropathy : a machine-assisted systematic review and meta-analysis. / Currie, Gillian L.; Angel-Scott, Helena N.; Colvin, Lesley; Cramond, Fala; Hair, Kaitlyn; Khandoker, Laila; Liao, Jing; MacLeod, Malcolm R.; McCann, Sarah K.; Morland, Rosie; Sherratt, Nicki; Stewart, Robert; Tanriver-Ayde, Ezgi; Thomas, James; Wang, Qianying; Wodarski, Rachel; Xiong, Ran; Rice, Andrew S. C.; Sena, Emily S. (Lead / Corresponding author).

In: PLoS Biology, Vol. 17, No. 5, e3000243, 20.05.2019, p. 1-34.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Animal models of chemotherapy-induced peripheral neuropathy

T2 - a machine-assisted systematic review and meta-analysis

AU - Currie, Gillian L.

AU - Angel-Scott, Helena N.

AU - Colvin, Lesley

AU - Cramond, Fala

AU - Hair, Kaitlyn

AU - Khandoker, Laila

AU - Liao, Jing

AU - MacLeod, Malcolm R.

AU - McCann, Sarah K.

AU - Morland, Rosie

AU - Sherratt, Nicki

AU - Stewart, Robert

AU - Tanriver-Ayde, Ezgi

AU - Thomas, James

AU - Wang, Qianying

AU - Wodarski, Rachel

AU - Xiong, Ran

AU - Rice, Andrew S. C.

AU - Sena, Emily S.

N1 - This work is part of the National centre for Replacement, Refinement and Reduction (NC3Rs, https://www.nc3rs.org.uk/) funded project; Reduction and refinement in animal models of neuropathic pain: using systematic review and meta-analysis (NC/K000659/1)- GLC, ES, MM, ASCR, JL, RS, NS, FC. This work is also part of the Europain Collaboration, which has received support from the Innovative Medicines Initiative Joint Undertaking, under grant agreement no 115007, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and EFPIA companies’ in kind contribution- ASCR. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 702213-SKM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

PY - 2019/5/20

Y1 - 2019/5/20

N2 - We report a systematic review and meta-analysis of research using animal models of chemotherapy-induced peripheral neuropathy (CIPN). We systematically searched 5 online databases in September 2012 and updated the search in November 2015 using machine learning and text mining to reduce the screening for inclusion workload and improve accuracy. For each comparison, we calculated a standardised mean difference (SMD) effect size, and then combined effects in a random-effects meta-analysis. We assessed the impact of study design factors and reporting of measures to reduce risks of bias. We present power analyses for the most frequently reported behavioural tests; 337 publications were included. Most studies (84%) used male animals only. The most frequently reported outcome measure was evoked limb withdrawal in response to mechanical monofilaments. There was modest reporting of measures to reduce risks of bias. The number of animals required to obtain 80% power with a significance level of 0.05 varied substantially across behavioural tests. In this comprehensive summary of the use of animal models of CIPN, we have identified areas in which the value of preclinical CIPN studies might be increased. Using both sexes of animals in the modelling of CIPN, ensuring that outcome measures align with those most relevant in the clinic, and the animal's pain contextualised ethology will likely improve external validity. Measures to reduce risk of bias should be employed to increase the internal validity of studies. Different outcome measures have different statistical power, and this can refine our approaches in the modelling of CIPN.

AB - We report a systematic review and meta-analysis of research using animal models of chemotherapy-induced peripheral neuropathy (CIPN). We systematically searched 5 online databases in September 2012 and updated the search in November 2015 using machine learning and text mining to reduce the screening for inclusion workload and improve accuracy. For each comparison, we calculated a standardised mean difference (SMD) effect size, and then combined effects in a random-effects meta-analysis. We assessed the impact of study design factors and reporting of measures to reduce risks of bias. We present power analyses for the most frequently reported behavioural tests; 337 publications were included. Most studies (84%) used male animals only. The most frequently reported outcome measure was evoked limb withdrawal in response to mechanical monofilaments. There was modest reporting of measures to reduce risks of bias. The number of animals required to obtain 80% power with a significance level of 0.05 varied substantially across behavioural tests. In this comprehensive summary of the use of animal models of CIPN, we have identified areas in which the value of preclinical CIPN studies might be increased. Using both sexes of animals in the modelling of CIPN, ensuring that outcome measures align with those most relevant in the clinic, and the animal's pain contextualised ethology will likely improve external validity. Measures to reduce risk of bias should be employed to increase the internal validity of studies. Different outcome measures have different statistical power, and this can refine our approaches in the modelling of CIPN.

UR - http://www.scopus.com/inward/record.url?scp=85066963826&partnerID=8YFLogxK

U2 - 10.1371/journal.pbio.3000243

DO - 10.1371/journal.pbio.3000243

M3 - Article

C2 - 31107871

VL - 17

SP - 1

EP - 34

JO - PLoS Biology

JF - PLoS Biology

SN - 1544-9173

IS - 5

M1 - e3000243

ER -